Genelux Corporation 卵巢癌三期试验(Onprime/GOG-3076)顶线数据将于2026年下半年公布

美股速递
Jan 05

Genelux Corporation宣布,其针对卵巢癌的三期临床试验(代号Onprime/GOG-3076)的顶线数据预计将在2026年下半年揭晓。该关键性试验结果的公布,将成为评估其候选疗法有效性与安全性的重要里程碑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10